Loading...
Dernières publications
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Pereon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
Joe-Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Leonard-Louis, Stéphane Ederhy, et al.. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discovery, 2023, 13 (5), pp.1100-1115. ⟨10.1158/2159-8290.CD-22-1180⟩. ⟨hal-04578810⟩
-
Corinna Preuße, Barbara Paesler, Christopher Nelke, Derya Cengiz, Thomas Müntefering, et al.. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144 (2), pp.353-372. ⟨10.1007/s00401-022-02438-z⟩. ⟨hal-03830925⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-03832478⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-04002766⟩
-
Stéphane Ederhy, Perrine Devos, Bruno Pinna, Elisa Funck-Brentano, Baptiste Abbar, et al.. 8 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography imaging for the diagnosis of immune checkpoint inhibitors associated myocarditis. Archives of cardiovascular diseases, 2022, ⟨10.1016/j.acvd.2021.12.001⟩. ⟨hal-03561783⟩
-
Pierre Bay, Marc Pineton de Chambrun, Vincent Rothstein, Matthieu Mahevas, Nicolas de Prost, et al.. Plasma exchange are not associated with better outcome in MDA5 rapidly-progressive interstitial lung disease. French Intensive Care Society International Congress 2022, 2022, paris, France. pp.54, ⟨10.1186/s13613-022-01016-6⟩. ⟨hal-03831253⟩
Chiffres clés
123
Publications avec texte intégral
Open Access
53 %
Mots clés
Interstitial lung disease
Anti-drug antibodies
Anti-interleukin-6
Antiphospholipid syndrome
Aldostérone
Machine learning
B cell homeostasis
Mass cytometry
Fabry disease
Middle Aged
Aged
Aldosterone
Anticorps anti-agalsidase
Inborn errors of metabolism
Animals
DM
Antisynthetase
Adverse drug reactions
Autoantibodies
Biomarker
B-lymphocyte
Antibodies
Anti‐mitochondrial antibodies
Antibody responses
Biomarqueurs
Myopathy
Lysosomal storage diseases
Amyotrophic lateral sclerosis
Auto-immunité
Autoimmune diseases
Adjudication
Amyotrophy
Biomarkers
Case reports
Active
Adolescence
Systems biology
IBM
Autoimmunity
COVID-19
Cardio-oncology
Myositis and muscle disease
Auto-antibodies
Cytokines
Acid-alpha-glucosidase
Immune checkpoint inhibitors
Analyses multidimensionnelles
Multidisciplinarity
Skeletal muscle
Pharmacology
Dependovirus/genetics/immunology
Interferon
Gene therapy
Polymyositis
Anémie hémolytique
Female
Male
AAV vectors
Immunotherapy
Autoantibody
Muscle
Cancer
Idiopathic inflammatory myopathies
Antisynthetase syndrome
Arthritis
Adult
AAV antibody
Prognosis
Anti-MDA5 autoantibodies
Myositis
Bioelectrical impedance analysis
Dermatomyositis
Acute Kidney Injury/epidemiology/etiology
Inclusion body myositis
Inflammation
AAV vector
Adeno-associated vector
Data integration
Humans
Adeno-associated virus
Assisted communication devices
Abnormal movement
Deep immune profiling
Agalsidase
Outcome measures
Biopsy
AAV
Anti-synthetase syndrome
Adeno-associated virus vector
Anticorps spécifique des myosites
Sphingosine-1-phosphate
Anti-agalsidase antibodies
Anti-IgE IgG
Inflammatory myopathy
AAV humoral immunity
Antisynthétase
Auto‐antibodies
Myocarditis
Anti-Mi2
IMNM